Le Lézard
Classified in: Health, Science and technology
Subjects: NEW PRODUCTS/SERVICES, HEALTH

Nubeva Successfully Decrypts Ransomware In Hospital Attack


SAN JOSE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Nubeva Technologies (TSX-V: NBVA, OTCQB: NBVAF) announces its success in decrypting live LockBit ransomware. This achievement is highlighted in a newly published case study, providing a detailed analysis of a targeted attack and successful recovery at a 240-bed hospital. The study showcases Nubeva's expertise in effectively decrypting ransomware, substantially reducing downtime costs, and minimizing damages within the critical industry.

"Persistent ransomware groups, including LockBit, BlackCat, Black Basta, and ClOP, are relentlessly targeting healthcare organizations," said Steve Perkins, CMO at Nubeva. "We are fully committed to empowering healthcare institutions with a simplified, rapid, and affordable solution to fortify their protection against such threats. We strongly urge these organizations to contact us immediately for a private briefing to explore how our advanced measures can effectively reduce risks."

In response to the growing threat in the industry, Nubeva is launching a promotional offering to reach vulnerable healthcare organizations. The campaign offers accelerated discounts and programs, enabling the immediate implementation of the company's Ransomware Reversal solution.

"Nubeva's 'Healthcare-Safety-Net' Program is a promotional campaign aimed at providing exclusive discounts and payment plans," explains Steve Perkins. "This program enables immediate implementation of Nubeva's Ransomware Reversal solution, allowing any health entity to fit it into their current budgets and reducing the risk of significant damages and interruption to their business and services."

Nubeva's Ransomware Reversal is a proactive system that can decrypt ransomed data, sight unseen, without paying ransoms. The solution delivers the fastest way to recover data and restore healthcare operations after an attack representing a new, essential safety net for every health organization to reduce the risk of significant downtime to patient care.

Contact Nubeva or join the healthcare-focused webinar on July 11th to learn more. The webinar will feature a live demonstration of Nubeva's cutting-edge technology, showcasing its effectiveness in defending against ransomware attacks. Attendees can engage in an interactive Q&A session with Nubeva's experts, gaining valuable insights into bolstering their ransomware resilience.

About Nubeva Technologies

Nubeva Technologies provides next-generation decryption solutions for faster, lower-cost recovery from ransomware attacks. Its mission is to reduce downtime costs and damages so businesses never pay ransoms again.

Nubeva's ransomware reversal software is available to end-user enterprises, managed security service providers, incident responders, and cybersecurity solution manufacturers. For a private briefing on Nubeva's ransomware decryption solutions, contact us.

For Investor Information - Visit our Investor Channel

Forward-looking statements

This news release contains "forward-looking information" and "financial outlook" within the meaning of applicable securities laws relating to the company's business plans, the outlook of the cybersecurity industry and the expectation that the company will be cash flow positive for calendar 2023. Although the company believes in light of the experience of its officers and directors, current conditions and expected future developments, and other factors that have been considered appropriate that the expectations reflected in this forward-looking information and financial outlook are reasonable, undue reliance should not be placed on them because the company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements for reasons relating to the development and adoption of the company's technology and its input and capital cost requirements, among other factors. The statements in this press release are made as of the date of this release, and the company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The company undertakes no obligation to comment on analyses, expectations, or statements made by third parties regarding the company, its subsidiaries, their securities, or their respective financial or operating results (as applicable).

Neither the TSX venture exchange nor its regulation services provider (as that term is defined in the policies of the TSX venture exchange) accepts responsibility for the adequacy or accuracy of this release.

For additional information or to schedule interviews, contact:

Steve Perkins
Chief Marketing Officer, Nubeva
[email protected]
(714) 261-9948



These press releases may also interest you

at 18:05
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

at 14:06
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

at 14:05
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

at 13:27
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

at 11:03
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

at 08:35
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...



News published on and distributed by: